Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

44.24
-1.3700-3.00%
Volume:45.48K
Turnover:2.03M
Market Cap:3.52B
PE:-11.78
High:45.31
Open:45.31
Low:43.98
Close:45.61
Loading ...

BRIEF-Akero Therapeutics Announces Upcoming Poster And Oral Presentations At The Easl Congress 2025

Reuters
·
Yesterday

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the Easl Congress 2025

THOMSON REUTERS
·
Yesterday

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

GlobeNewswire
·
Yesterday

Akero Therapeutics initiated with a Buy at Clear Street

TIPRANKS
·
Yesterday

Chief Scientific Officer Timothy Rolph Reports Disposal of Akero Therapeutics Common Shares

Reuters
·
29 Apr

Major Investment Alert: Akero Therapeutics Stock Purchase by Director!

TIPRANKS
·
28 Mar

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Zacks
·
04 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar

Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
03 Mar

Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics

TIPRANKS
·
03 Mar

Akero Therapeutics price target lowered to $90 from $96 at Morgan Stanley

TIPRANKS
·
03 Mar

Bank of America Securities Remains a Buy on Akero Therapeutics (AKRO)

TIPRANKS
·
02 Mar

Akero Therapeutics: Buy Rating Backed by Groundbreaking Clinical Results and Strong Financial Position

TIPRANKS
·
02 Mar

Akero Therapeutics Reports Promising Clinical Trial Results

TIPRANKS
·
01 Mar

Akero Therapeutics: Strong Financial Health and Promising Clinical Trial Results Drive Buy Rating

TIPRANKS
·
01 Mar

Akero Therapeutics Inc - Q4 Shr Loss $0.99

THOMSON REUTERS
·
28 Feb

Akero Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Akero Therapeutics Q4 Loss Unchanged

MT Newswires Live
·
28 Feb

Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Total Operating Expenses $78M

MT Newswires Live
·
28 Feb

Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?

Insider Monkey
·
28 Feb